Abstract
Lung cancer is the most common cause of malignant pleural effusions (MPEs). For patients with lung cancer and MPE, median survival is only 3-4 months. The aim of this study was to evaluate lung cancer patients with MPE by clinical and laboratory findings on admission, and determine 2-year survival rate and prognostic factors. Between 2008 and 2011, we examined 199 cases of non-small cell lung carcinoma with MPE. Demographic factors of patients, tumor characteristics, treatment delivered and laboratory parameters affecting prognosis were evaluated. Survival rates were estimated by Kaplan-Meier method. Significance of each prognostic factors selected by univariate analysis were confirmed using Cox regression model. The study included 139 (69.8%) male and 60 (30.2%) female patients with a median age of 64 (30-85) years. Median overall survival was 4.4 months. Adenocarcinoma was the leading cause of MPE with 80.4%. A univariate analysis showed that factors affecting mortality included gender (P < 0.001), MPE with distant metastasis (P = 0.025), lower serum albumin (P < 0.0001), lower pleural protein (P < 0.0001), increased serum lactate dehydrogenase (P = 0.003), increased serum C-reactive protein (CRP) (P < 0.0001), increased whit...Continue Reading
References
May 1, 1985·Chest·A CantóR Bernat
Aug 1, 1996·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·N TakigawaM Fujii
Jan 13, 2000·Chest·C M BurrowsH G Colt
Jan 13, 2000·Chest·J E HeffnerC Barbieri
Aug 19, 2007·Cancer·S-H Ignatius OuHoda Anton-Culver
Dec 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Taofeek K OwonikokoSuresh S Ramalingam
Mar 21, 2009·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Li-Han HsuAn-Chen Feng
Aug 28, 2010·Thorax·Mark E RobertsUNKNOWN BTS Pleural Disease Guideline Group
Aug 11, 2010·Current Oncology·G KasymjanovaD Small
Aug 31, 2010·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·John E PillingPeter Goldstraw
Dec 22, 2011·Yonsei Medical Journal·Soojung HongDae Joon Kim
Sep 29, 2012·The European Respiratory Journal·Shang-Gin WuJin-Yuan Shih
Mar 5, 2013·Canadian Respiratory Journal : Journal of the Canadian Thoracic Society·Marshall W PitzSrisala Navaratnam
May 10, 2013·Chest·Mark A SocinskiThomas E Stinchcombe
Jun 8, 2013·Journal of the National Comprehensive Cancer Network : JNCCN·David S EttingerUNKNOWN National comprehensive cancer network
Nov 2, 2013·Oncology Letters·Faruk TasSenem Karabulut
Nov 19, 2013·The Medical Journal of Australia·Paul L R MitchellGavin M Wright
Citations
Dec 19, 2016·International Journal of Clinical Oncology·Mei FengFuqiang Wen
Apr 21, 2017·Current Opinion in Pulmonary Medicine·Labib G Debiane, David E Ost
Jul 12, 2017·Cancers·Ilija NenadićOliver Schildgen
Jul 14, 2018·PloS One·Jeong Uk LimSang Haak Lee
Aug 16, 2018·Journal of Oncology Practice·Theresa S YangDong W Chang
Sep 22, 2018·Medicine·Taibing DengWeimin Li
Apr 5, 2019·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Janet Rodríguez-TorresMarie Carmen Valenza
May 18, 2017·Oncotarget·Guo-Jun LuHui Kong
Nov 16, 2017·Oncotarget·Carl-Olof HillerdalAnders Hjerpe
Aug 4, 2016·Oncotarget·Fanming KongYingjie Jia
Apr 16, 2020·The Clinical Respiratory Journal·Jaehee LeeChang Ho Kim
Aug 18, 2020·Journal of Bronchology & Interventional Pulmonology·Russell J MillerRoberto F Casal
Apr 3, 2020·Scientific Reports·Bahil GhanimClemens Aigner
Jan 30, 2021·Future Oncology·Larissy Machado da SilvaLuiz Claudio Santos Thuler
Mar 6, 2021·Chest·Eleanor K MishraNajib M Rahman
Apr 15, 2021·Chest·Sofia MolinaDavid E Ost
Jun 10, 2021·Medicine·Jiyeon RohJung Seop Eom